🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. Matching Placebo for Test, SAR443765 / LUNSEKIMIG

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 small molecule active

    1 trial

  2. Matching Placebo tablets without active substance, BIIB122

    Biogen

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  3. Matching film-coated placebo tablet

    Bioprojet Pharma

    Obsessive compulsive disorder

    phase 2 small molecule active

    1 trial

  4. Matching orodispersible placebo tablet

    Bioprojet Pharma

    Eosinophilic esophagitis

    phase 2 small molecule active

    1 trial

  5. Matching placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Familial Dysautonomia

    phase 2 small molecule active

    1 trial

  6. Matching placebo for Survodutide, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Disc Medicine

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial

  7. Matching placebo tablets without active substance, BI 706321, BI 706321, BI 706321, STELARA 130 mg concentrate for solution for infusion, STELARA 90 mg solution for injection in pre-filled pen

    Boehringer Ingelheim

    Crohn`s Disease (CD)

    phase 2 small molecule active

    1 trial

  8. Mivelsiran, Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain

    phase 2 small molecule active

    1 trial

  9. NANOBODY® Placebo; The placebo is a standard placebo formulation containing common excipients for NANOBODY drug products and is used by Sanofi for NANOBODY clinical studies., SAR442970

    Sanofi-aventis Healthcare Pty Ltd

    Crohn’s disease

    phase 2 small molecule active

    1 trial

  10. NAPROXEN SODIUM, DESOGESTREL, TRAMADOL HYDROCHLORIDE, IBUPROFEN, Placebo to match AMY109, Placebo to match desogestrel, Feanolla 75 microgram film-coated tablets, CODEINE PHOSPHATE, PARACETAMOL, NAPROXEN, AMY109

    Lacuna Pharma Pty Ltd

    Endometriosis

    phase 2 small molecule active

    1 trial

  11. NAT01, NAT03, Placebo film coated tablets, NAT02

    Dr. Falk Pharma GmbH

    Idiopathic or Diabetic Gastroparesis

    phase 2 small molecule active

    1 trial

  12. NBI-1117570, NBI-1117570, Placebo for nbi-1117570

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule active

    1 trial

  13. NKTR-358, Placebo

    Nektar Therapeutics UK Limited

    Alopecia Areata

    phase 2 small molecule active

    1 trial

  14. NMD670, NMD670, Placebo

    Lacuna Pharma Pty Ltd

    Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  15. NMD670, Placebo

    Lacuna Pharma Pty Ltd

    Charcot-Marie-Tooth Disease Type 1 and Type 2

    phase 2 small molecule active

    1 trial

  16. NOE-105, Placebo, Hard Capsules

    Lacuna Pharma Pty Ltd

    Tourette Syndrome

    phase 2 small molecule active

    1 trial

  17. Nalbuphine ER, Placebo - Nalbuphine ER, Nalbuphine ER

    Trevi Therapeutics

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  18. Namodenoson, Matching placebo for namodenoson

    Can-Fite BioPharma

    Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

    phase 2 small molecule active

    1 trial

  19. Natrunix with MTX placebo (+folate)

    XBiotech Germany GmbH

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  20. NoV Placebo-matching Saline

    Takeda

    Healthy Volunteers

    phase 2 mab completed

    1 trial

  21. Normix 200 mg compresse rivestite con film, The placebo is a film-coated oral tablet designed to be comparable in appearance, administration, and handling to the investigational medicinal product (rifaximin 200 mg film-coated tablets), while containing no active pharmaceutical ingredient. The placebo consists exclusively of commonly used pharmaceutical excipients with established safety profiles and is administered solely to maintain blinding in the clinical trial.

    Fondazione Telethon ETS

    substance use disorder

    phase 2 small molecule active

    1 trial

  22. OCALIVA, Placebo for Bezafibrate, Bezalip Mono, Placebo for Obeticholic Acid, Bezalip, OCALIVA

    Lacuna Pharma Pty Ltd

    Primary Biliary Cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  23. ODM-111 Placebo, Para-Tabs 500 mg tabletti, ODM-111, ODM-111

    Orion Laboratories Pty.

    Chronic Pain due to Ostheoarthritis of the knee

    phase 2 small molecule active

    1 trial

  24. ORKA-001, Placebo for ORKA-001

    Oruka Therapeutics

    Moderate-to-Severe Plaque Psoriasis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources